Clinical Trial Update: Intranasal Modified Vacc-4x Gag Peptides With Endocine as Adjuvant [Phase 1, Phase 2]

View source ↗

Summary

Update on a Phase 1/2 HIV vaccine trial using intranasal Modified Vacc-4x Gag peptides with Endocine as adjuvant; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Endocine adjuvant (Endocine)
• Vacc-4x Gag peptide (Vacc-4x Gag peptide)

Snippet

Sponsor: Oslo University Hospital | Conditions: HIV Infection | Phase 1, Phase 2 | Status: COMPLETED